The news directly mentions Enfusion (NYSE:ENFN) and the lowered price target by Piper Sandler analyst Sumeet Mody. This may cause short-term uncertainty among investors, but the Neutral rating suggests no significant change in the stock's overall outlook. Therefore, the short-term impact on the stock price is expected to be neutral.